Selective α3β4 Nicotinic Acetylcholine Receptor Ligand as a Potential Tracer for Drug Addiction

被引:2
|
作者
Kanasuwan, Apinan [1 ,2 ]
Deuther-Conrad, Winnie [3 ]
Chongruchiroj, Sumet [4 ]
Sarasamkan, Jiradanai [5 ]
Chotipanich, Chanisa [2 ]
Vajragupta, Opa [6 ]
Arunrungvichian, Kuntarat [1 ]
机构
[1] Mahidol Univ, Fac Pharm, Dept Pharmaceut Chem, 447 Sri Ayutthaya Rd, Bangkok 10400, Thailand
[2] Chulabhorn Royal Acad, Chulabhorn Hosp, Natl Cyclotron & PET Ctr, 906 Kamphaengphet 6 Rd, Bangkok 10210, Thailand
[3] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut Canc Res, Dept Neuroradiopharmaceut, Permoserstr 15, D-04318 Leipzig, Germany
[4] Mahidol Univ, Fac Pharm, Dept Microbiol, 447 Sri Ayutthaya Rd, Bangkok 10400, Thailand
[5] Khon Kaen Univ, Fac Med, Dept Radiol, 123 Mittraphap Rd, Khon Kaen 40002, Thailand
[6] Chulalongkorn Univ, Fac Pharmaceut Sci, Mol Probes Imaging Res Network, 254 Phayathai Rd, Bangkok 10330, Thailand
关键词
alpha(3)beta(4) Nicotinic acetylcholine receptor; quinuclidine; triazole; drug-seeking behavior monitoring; drug addiction; INTERPEDUNCULAR NUCLEUS; GENE-CLUSTER; AFFINITY; METHAMPHETAMINE; RADIOLIGAND; ANTAGONIST; WITHDRAWAL; COCAINE; AT-1001; TARGETS;
D O I
10.3390/ijms24043614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha(3)beta(4) Nicotinic acetylcholine receptor (nAChR) has been recognized as an emerging biomarker for the early detection of drug addiction. Herein, alpha(3)beta(4) nAChR ligands were designed and synthesized to improve the binding affinity and selectivity of two lead compounds, (S)-QND8 and (S)-T2, for the development of an alpha(3)beta(4) nAChR tracer. The structural modification was achieved by retaining the key features and expanding the molecular structure with a benzyloxy group to increase the lipophilicity for blood-brain barrier penetration and to extend the ligand-receptor interaction. The preserved key features are a fluorine atom for radiotracer development and a p-hydroxyl motif for ligand-receptor binding affinity. Four (R)- and (S)-quinuclidine-triazole (AK1-AK4) were synthesized and the binding affinity, together with selectivity to alpha(3)beta(4) nAChR subtype, were determined by competitive radioligand binding assay using [H-3]epibatidine as a radioligand. Among all modified compounds, AK3 showed the highest binding affinity and selectivity to alpha(3)beta(4) nAChR with a K-i value of 3.18 nM, comparable to (S)-QND8 and (S)-T2 and 3069-fold higher affinity to alpha(3)beta(4) nAChR in comparison to alpha(7) nAChR. The alpha(3)beta(4) nAChR selectivity of AK3 was considerably higher than those of (S)-QND8 (11.8-fold) and (S)-T2 (294-fold). AK3 was shown to be a promising alpha(3)beta(4) nAChR tracer for further development as a radiotracer for drug addiction.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] The dopamine D3 receptor and drug addiction
    Sokoloff, Pierre
    Le Foll, Bernard
    Perachon, Sylvie
    Bordet, Regis
    Ridray, Sophie
    Schwartz, Jean-Charles
    NEUROTOXICITY RESEARCH, 2001, 3 (05) : 433 - 441
  • [32] Synthesis and biological evaluation of novel hybrids of highly potent and selective α4β2-Nicotinic acetylcholine receptor (nAChR) partial agonists
    Zhang, Han-Kun
    Eaton, J. Brek
    Fedolak, Allison
    Gunosewoyo, Hendra
    Onajole, Oluseye K.
    Brunner, Dani
    Lukas, Ronald J.
    Yu, Li -Fang
    Kozikowski, Alan P.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 124 : 689 - 697
  • [33] Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit
    Salas, R
    Pieri, F
    De Biasi, M
    JOURNAL OF NEUROSCIENCE, 2004, 24 (45) : 10035 - 10039
  • [34] Toll-Like Receptor 4 Signaling and Drug Addiction
    Wu, Ruyan
    Li, Jun-Xu
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [35] A Novel α4/7-Conotoxin QuIA Selectively Inhibits α3β2 and α6/α3β4 Nicotinic Acetylcholine Receptor Subtypes with High Efficacy
    Wang, Liujun
    Wu, Xixi
    Zhu, Xiaopeng
    Zhangsun, Dongting
    Wu, Yong
    Luo, Sulan
    MARINE DRUGS, 2022, 20 (02)
  • [36] Single-Disulfide Conopeptide Czon1107, an Allosteric Antagonist of the Human α3β4 Nicotinic Acetylcholine Receptor
    Ma, Yuan
    Cao, Qiushi
    Yang, Mengke
    Gao, Yue
    Fu, Shuiping
    Du, Wenhao
    Adams, David J.
    Jiang, Tao
    Tae, Han-Shen
    Yu, Rilei
    MARINE DRUGS, 2022, 20 (08)
  • [37] From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor
    Bolchi, Cristiano
    Bavo, Francesco
    Gotti, Cecilia
    Fumagalli, Laura
    Fasoli, Francesca
    Binda, Matteo
    Mucchietto, Vanessa
    Sciaccaluga, Miriam
    Plutino, Simona
    Fucile, Sergio
    Pallavicini, Marco
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 125 : 1132 - 1144
  • [38] Pharmacological properties and predicted binding mode of arylmethylene quinuclidine-like derivatives at the α3β4 nicotinic acetylcholine receptor (nAChR)
    Kombo, David C.
    Hauser, Terry A.
    Grinevich, Vladimir P.
    Melvin, Matthew S.
    Strachan, Jon-Paul
    Sidach, Serguei S.
    Chewning, Joseph
    Fedorov, Nikolai
    Tallapragada, Kartik
    Breining, Scott R.
    Miller, Craig H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) : 1450 - 1455
  • [39] What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders
    Straub, Carolyn J.
    Rusali, Lisa E.
    Kremiller, Kyle M.
    Riley, Andrew P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (01) : 107 - 121
  • [40] Reduced Expression of Ethanol Sensitization by α3β4 Nicotinic Acetylcholine Receptors in DBA/2J Mice
    Miller, Carley N.
    Kamens, Helen M.
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2020, 28 (03) : 348 - 354